Cure My Disease
Don't miss your cure!
Clinical trials sponsored by Modulation Therapeutics, Inc., explained in plain language.
This early-phase study tests a radioactive drug called 225Ac-MTI-201 in 16 people with metastatic uveal melanoma, a rare eye cancer that has spread. The main goal is to find the highest safe dose and understand side effects. Participants must have already tried at least one other…
Phase: PHASE1 • Sponsor: Modulation Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC